KEAP1 and cancer: Another interesting aspect is that the occurrence of KEAP1 and NRF2 mutations is mutually exclusive in cancer patients, suggesting that targeting either KEAP1 or NRF2 is sufficient to activate ARE-dependent gene expression in cancer.